In the preclinical literature, BPC-157 is described primarily in context connective tissue reparation models of Achilles tendon rupture and cutting, ligament and muscle damage and protection of the digestive tract (models of stomach ulcers, colitis)
Side Effects & Safety Mild GI discomfort most common, usually transient in the first week Slight stimulant effect increased energy/alertness, especially early on Headaches occasional, typically mild and dose-related Mild insomnia if taken too late in the day No human clinical safety data all safety information from preclinical studies and community reports No liver toxicity observed in animal studies at therapeutic doses Unknown drug interactions theoretically could interact with NAD+-dependent pathways Core Supplies for This Protocol The three essentials for running any reconstituted injectable: cold storage, accurate syringes, and metabolic tracking
However, neurodegenerative disease mechanisms differ substantially between animal models and human diseases, and premature clinical use based solely on animal data could expose patients to unknown risks without established benefits
TB-500 has potent anti-inflammatory properties that go beyond the local injury site
